ANIDULAFUNGIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C58H73N7O17
Molecular Weight	1140.2369
Optical Activity	UNSPECIFIED
Defined Stereocenters	15 / 15
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@@H](O)CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)[C@H](O)[C@@H](O)C7=CC=C(O)C=C7)[C@@H](C)O

InChI

InChIKey=JHVAMHSQVVQIOT-MFAJLEFUSA-N

InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C58H73N7O17
Molecular Weight	1140.2369
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	15 / 15
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf

Anidulafungin (brand names Eraxis (in U.S. and Russia) and Ecalta (in Europe)) is a semi-synthetic echinocandin with antifungal activity and it is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes. This drug is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis; and for the treatment of esophageal candidiasis. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3--D-glucan, an essential component of the fungal cell wall.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
1,3-beta-glucan synthase 10 Target ID: CHEMBL2364673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18473501	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Candidemia 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Curative		Approved 8583	ERAXIS Approved Use ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly. Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) (1.1) Esophageal candidiasis (1.2) Limitations of use: has not been studied in endocarditis, osteomyelitis and meningitis due to Candida or in sufficient numbers of neutropenic patients (1.3) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis [see Clinical Studies(14.1) and Clinical Pharmacology, Microbiology (12.4) Launch Date 2006
Esophageal candidiasis 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Curative		Approved 8583	ERAXIS Approved Use ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly. Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) (1.1) Esophageal candidiasis (1.2) Limitations of use: has not been studied in endocarditis, osteomyelitis and meningitis due to Candida or in sufficient numbers of neutropenic patients (1.3) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis [see Clinical Studies(14.1) and Clinical Pharmacology, Microbiology (12.4) Launch Date 2006

C_max

Value	Dose	Co-administered	Analyte	Population
4.2 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.2 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
55.2 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
110.3 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
26.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	unhealthy, 16-89 Health Status: unhealthy Age Group: 16-89 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Disc. AE: Multi-organ failure... AEs leading to discontinuation/dose reduction: Multi-organ failure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23676114	unhealthy, 56.5 (± 18.5) Health Status: unhealthy Age Group: 56.5 (± 18.5) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/23676114	Disc. AE: Drug hypersensitivity, Skin rash... AEs leading to discontinuation/dose reduction: Drug hypersensitivity (2.3%) Skin rash (2.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/23676114
400 mg single, intravenous Overdose Dose: 400 mg Route: intravenous Route: single Dose: 400 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Disc. AE: Abnormal liver function tests, Hepatitis... AEs leading to discontinuation/dose reduction: Abnormal liver function tests Hepatitis Hepatic failure Hypersensitivity Anaphylaxis Rash Urticaria Flushing Pruritus Bronchospasm Dyspnea Hypotension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 110 CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 P-gp 1741 BCRP 910	P-gp 2052 CYP 303	CYP 74

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	inconclusive
CYP 150	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	no
CYP 150	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	no
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: voriconazole did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: voriconazole did not significantly alter anidulafungin pharmacokinetics; rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: cyclosporine did not significantly alter anidulafungin pharmacokinetics; voriconazole did not significantly alter anidulafungin pharmacokinetics; rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
BCRP 985	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	strong [IC50 7 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	inconclusive
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44, 54	no		no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44, 54

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:55346	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:55346
ChemicalBook	CB71120054	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB71120054
eMolecules	36905381	https://www.emolecules.com/cgi-bin/more?vid=36905381
MolPort	MolPort-006-167-527	https://www.molport.com/shop/molecule-link/MolPort-006-167-527

PubMed

Title	Date	PubMed
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.	2008-08	18458136
[Anidulafungin in the invasive fungal infection: current topics].	2008-06	18473499
Liposomal amphotericin B: what is its role in 2008?	2008-05	18430132
Stimulation of chitin synthesis rescues Candida albicans from echinocandins.	2008-04-04	18389063
Management of Candida infections in the adult intensive care unit.	2008-02	18201143
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.	2008-02	18070979
Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.	2008-02	18057972
Propofol lipidic infusion promotes resistance to antifungals by reducing drug input into the fungal cell.	2008-01-17	18201378
Anidulafungin was noninferior to fluconazole for invasive candidiasis.	2008-01-04	18171002
Early clinical experience with anidulafungin at a large tertiary care medical center.	2008-01	18154476
Bench-to-bedside review: Candida infections in the intensive care unit.	2008	18279532
Advances in antifungal therapy.	2008	17967129
[In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms].	2007-12-31	18095759
A review of the new antifungals: posaconazole, micafungin, and anidulafungin.	2007-12	18189069
Update on new antifungal therapy.	2007-11-21	18019516
Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies?	2007-11	18221175
Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases.	2007-11	17900699
Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients.	2007-10	17646966
Anidulafungin and fluconazole for candidiasis.	2007-09-27	17902202
Anidulafungin and fluconazole for candidiasis.	2007-09-27	17898107
Recent advances in antifungal agents.	2007-09	17897080
Susceptibility patterns of Candida species recovered from Canadian intensive care units.	2007-09	17869976
Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.	2007-08	18472974
One year prospective survey of Candida bloodstream infections in Scotland.	2007-08	17644714
A comparative evaluation of properties and clinical efficacy of the echinocandins.	2007-07	17661730
Nongastroesophageal reflux disease-related infectious, inflammatory and injurious disorders of the esophagus.	2007-07	17545784
Development of anidulafungin for disk diffusion susceptibility testing against Candida spp.	2007-07	17376633
Echinocandins--first-choice or first-line therapy for invasive candidiasis?	2007-06-14	17568034
Anidulafungin versus fluconazole for invasive candidiasis.	2007-06-14	17568028
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.	2007-04	17389555
Comparison of echinocandin antifungals.	2007-03	18360617
Essential gene identification and drug target prioritization in Aspergillus fumigatus.	2007-03	17352532
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.	2007-03	17322142
The echinocandins.	2007-03	17316149
New drugs 07, part I.	2007-02	17273084
Anidulafungin: a new echinocandin for candidal infections.	2007-02	17266452
Antifungal agents in neonates: issues and recommendations.	2007	17927303
Role of micafungin in the antifungal armamentarium.	2007	17504145
Anidulafungin--state of affairs from a clinical perspective.	2007	17394608
Fungal infections of the CNS: treatment strategies for the immunocompromised patient.	2007	17381184
The safety of anidulafungin.	2006-11	17044802
Echinocandins in the management of invasive fungal infections, Part 2.	2006-10-01	16990627
Echinocandins in the management of invasive fungal infections, part 1.	2006-09-15	16960253
Echinocandins for candidemia in adults without neutropenia.	2006-09-14	16971721
Gateways to clinical trials.	2006-09	17003851
Another option for fungal infections.	2006-08-16	16906658
Anidulafungin: a new echinocandin for the treatment of fungal infections.	2006-08	16969430
Voriconazole in the management of nosocomial invasive fungal infections.	2006-06	18360588
Gateways to clinical trials.	2006-05	16801985
The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.	2006	17047411

Patents

Sample Use Guides

In Vivo Use Guide

Candidemia and other Candida infections (intra-abdominal abscess, and peritonitis) The recommended dose is a single 200 mg loading dose on Day 1, followed by 100 mg daily dose thereafter. Duration of treatment should be based on the patient’s clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture. Esophageal Candidiasis: The recommended dose is a single 100 mg loading dose on Day 1, followed by 50 mg daily dose thereafter. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms. Duration of treatment should be based on the patient’s clinical response. Because of the risk of relapse of esophageal candidiasis in patients with HIV infections, suppressive antifungal therapy may be considered after a course of treatment.

Route of Administration: Intravenous

In Vitro Use Guide

A 48 hours exposure of human erythrocytes to Anidulafungin (1.5 - 6 µg/ml) significantly increased hemolysis and the percentage of annexin-V-binding cells, and significantly decreased forward scatter. Anidulafungin (6 µg/ml) slightly, but significantly inceased Fluo3-fluorescence and the effect of Anidulafungin on annexin-V-binding was slightly, but significantly blunted by removal of extracellular Ca2+. The effect of Anidulafungin on annexin-V-binding was further significantly blunted by the p38 kinase inhibitor SB203580 (2 µM) and NO donor nitroprusside (1 µM). An increase of extracellular K+ concentration significantly blunted the effect of Anidulafungin on cell volume but not on annexin-V-binding.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:24:12 GMT 2025` Edited by `admin` on `Mon Mar 31 18:24:12 GMT 2025`
Record UNII	9HLM53094I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ERAXIS

Preferred Name

English

ANIDULAFUNGIN

Official Name

English

VER002

Code

English

LY-303366

Code

English

ANIDULAFUNGIN [ORANGE BOOK]

Common Name

English

Anidulafungin [WHO-DD]

Common Name

English

D70013

Code

English

ANIDULAFUNGIN [VANDF]

Common Name

English

LY303366

Code

English

ANIDULAFUNGIN [USAN]

Common Name

English

ECHINOCANDIN B, 1-((4R,5R)-4,5-DIHYDROXY-N(SUP 2)-((4''-(PENTYLOXY)(1,1':4',1''-TERPHENYL)-4-YL)CARBONYL)-L-ORNITHINE)-

Common Name

English

V-ECHINOCANDIN

Common Name

English

(4R,5R)-4,5-DIHYDROXY-N(SUP 2)-((4''-(PENTYLOXY)-P-TERPHENYL-4-YL)CARBONYL)-L-ORNITHYL-L-THREONYL-TRANS-4-HYDROXY-L-PROLYL-(S)-4-HYDROXY-4-(P-HYDROXYPHENYL)-L-THREONYL-L-THREONYL-(3S,4S)-3-HYDROXY-4-METHYL-L-PROLINE CYCLIC (6->1)-PEPTIDE

Common Name

English

VER-002

Code

English

ANIDULAFUNGIN [MART.]

Common Name

English

ANIDULAFUNGIN [EMA EPAR]

Common Name

English

D-70013

Code

English

anidulafungin [INN]

Common Name

English

ANIDULAFUNGIN [MI]

Common Name

English

Classification Tree Code System Code

LIVERTOX

58